Frontier Capital Management Co. LLC boosted its stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 351.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 698,694 shares of the biotechnology company’s stock after buying an additional 543,809 shares during the period. Frontier Capital Management Co. LLC owned 0.74% of Adaptimmune Therapeutics worth $9,474,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in ADAP. BlackRock Inc. grew its position in Adaptimmune Therapeutics by 2.5% in the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after buying an additional 19,765 shares in the last quarter. JPMorgan Chase & Co. grew its position in Adaptimmune Therapeutics by 786.0% in the 1st quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock valued at $2,085,000 after buying an additional 164,704 shares in the last quarter. Jane Street Group LLC bought a new position in Adaptimmune Therapeutics in the 1st quarter valued at about $168,000. Atria Investments LLC bought a new position in Adaptimmune Therapeutics in the 2nd quarter valued at about $221,000. Finally, Baillie Gifford & Co. grew its position in Adaptimmune Therapeutics by 18.2% in the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after buying an additional 467,852 shares in the last quarter. Hedge funds and other institutional investors own 59.09% of the company’s stock.
In other Adaptimmune Therapeutics news, major shareholder Enterprise Associates 14 New acquired 3,000,000 shares of Adaptimmune Therapeutics stock in a transaction dated Friday, September 7th. The stock was bought at an average price of $1.67 per share, for a total transaction of $5,010,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total transaction of $256,250.00. The disclosure for this sale can be found here. Company insiders own 26.47% of the company’s stock.
NASDAQ:ADAP opened at $7.09 on Friday. Adaptimmune Therapeutics PLC – has a twelve month low of $5.73 and a twelve month high of $14.63.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%. The business had revenue of $9.04 million for the quarter, compared to the consensus estimate of $7.76 million. As a group, analysts expect that Adaptimmune Therapeutics PLC – will post -1.01 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on ADAP shares. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, August 15th. Raymond James decreased their target price on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, October 22nd. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Guggenheim started coverage on shares of Adaptimmune Therapeutics in a research report on Monday, September 17th. They issued a “buy” rating for the company. Finally, ValuEngine lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 22nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $15.44.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Featured Story: Dollar Cost Averaging
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.